Adaptive Biotechnologies makes immune system based cancer tests and sells immune data to clinicians and drug developers. ADPT reports earnings on Wed, Nov 4, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (5 buy, 1 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for ADPT are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ADPT is in one of them and how their past ADPT trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Adaptive Biotechnologies
Adaptive Biotechnologies is a life sciences company based in Seattle, Washington. It uses sequencing and data analysis of the immune system to develop medical tests and products. Its main product, clonoSEQ, measures residual disease in patients with blood cancers and is sold to clinicians. It also runs testing for biopharmaceutical companies developing new drugs and licenses its immune system data to drug developers.
